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ABSTRACT
Small intestinal mucosal injury is a frequent adverse effect
caused by nonsteroidal anti-inflammatory drugs (NSAIDs). The
underlying mechanisms are not completely understood, but
topical (luminal) effects have been implicated. Many carboxylic
acid-containing NSAIDs, including diclofenac (DCF), are me-
tabolized to acyl glucuronides (AGs), and/or ether glucuronides
after ring hydroxylation, and exported into the biliary tree. In the
gut, these conjugates are cleaved by bacterial -glucuronidase,
releasing the potentially harmful aglycone. We first confirmed
that DCF-AG was an excellent substrate for purified Escherichia
coli -D-glucuronidase. Using a previously characterized novel
bacteria-specific -glucuronidase inhibitor (Inhibitor-1), we
then found that the enzymatic hydrolysis of DCF-AG in vitro
was inhibited concentration dependently (IC50 164 nM). We
next hypothesized that pharmacologic inhibition of bacterial
-glucuronidase would reduce exposure of enterocytes to the
aglycone and, as a result, alleviate enteropathy. C57BL/6J mice
were administered an ulcerogenic dose of DCF (60 mg/kg i.p.)
with or without oral pretreatment with Inhibitor-1 (10 g per
mouse, b.i.d.). Whereas DCF alone caused the formation of
numerous large ulcers in the distal parts of the small intestine
and increased (2-fold) the intestinal permeability to fluorescein
isothiocyanate-dextran, Inhibitor-1 cotreatment significantly al-
leviated mucosal injury and reduced all parameters of enterop-
athy. Pharmacokinetic profiling of DCF plasma levels in mice
revealed that Inhibitor-1 coadministration did not significantly
alter the Cmax, half-life, or area under the plasma concentration
versus time curve of DCF. Thus, highly selective pharmacologic
targeting of luminal bacterial -D-glucuronidase by a novel
class of small-molecule inhibitors protects against DCF-in-
duced enteropathy without altering systemic drug exposure.
Introduction
Gastrointestinal (GI) injury is one of the major adverse
effects associated with nonsteroidal anti-inflammatory drugs
(NSAIDs). This iatrogenic disease is manifested as ulceration
and bleeding of the mucosa, inflammation, and even perfo-
ration (Allison et al., 1992; Bjarnason et al., 1993; Wolfe et
al., 1999). With the advent of novel diagnostic tools, including
video capsule endoscopy, it has become increasingly clear
that not only the stomach, but also the small intestine, is a
major target of NSAID-associated toxicity (Davies et al.,
2000; Koga et al., 2008; Scarpignato and Hunt, 2010). Indeed,
approximately two-thirds of both long-term (3 months) and
short-term (1 week) NSAID users exhibited mild or more
severe forms of drug-induced lesions in the small intestine
(Fortun and Hawkey, 2007; Maiden, 2009). In addition, many
unexplained GI lesions in “control subjects” were found to be
attributable to nonprescription use of NSAIDs (Sidhu et al.,
2010). Despite this high incidence of the disease, there are
currently no approved therapies to prevent or treat NSAID
enteropathy.
Part of the reasons for a lack of therapies is an incomplete
understanding of the underlying mechanisms (Whittle,
2004). The mode of toxicity to the small intestinal mucosa is
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clearly distinct from that involved in the precipitation of
gastric lesions induced by NSAIDs. For example, although
inhibition of COX-1 and/or COX-2 may contribute to the
toxicity (Sigthorsson et al., 2002; Tanaka et al., 2002; Hotz-
Behofsits et al., 2010), there are also off-target adverse ef-
fects involved (Somasundaram et al., 1997). These “topical
effects” are thought to be mediated by the glucuronide con-
jugates of NSAIDs (and/or their oxidative metabolites), the
major export form delivering the NSAIDs from the hepatobi-
liary system to the small intestinal lumen. Here, the conju-
gates are enzymatically cleaved by -glucuronidases, and the
aglycone is reabsorbed (Seitz and Boelsterli, 1998; Treinen-
Moslen and Kanz, 2006). Locally high intracellular levels of
NSAIDs, combined with COX inhibition, may then initiate a
cascade of events leading to epithelial damage and entailing
an inflammatory response, which is triggered by increases in
the permeability of the gut mucosa. This allows intestinal
bacterial lipopolysaccharide to activate Toll-like receptor 4
on macrophages, leading to tumor necrosis factor-mediated
cell injury and secondary activation of the innate immune
system and recruitment of inflammatory cells to the site of
injury (Watanabe et al., 2008). Previous studies have aimed
at targeting one or more of these pathways in an attempt to
develop cytoprotective strategies against NSAID enteropathy
(Watanabe et al., 2008; Ramirez-Alcantara et al., 2009;
LoGuidice et al., 2010; Yamada et al., 2011). Here, we sought
to target a mechanism that would provide effective protection
against NSAID enteropathy upstream of these primary and
secondary events by limiting the initial exposure of the in-
testinal mucosa to the drug.
This novel strategy is based on a characteristic pharmaco-
kinetic feature of diclofenac (DCF) and other carboxylic acid-
containing NSAIDs. A portion of the hepatic diclofenac pool is
conjugated with glucuronic acid to form a water-soluble 1--
O-acyl glucuronide. This acyl glucuronide (AG) is readily
excreted across the hepatocanalicular membrane via ATP-
binding cassette sub-family C member 2 (ABCC; MRP2) into
the biliary tree (Seitz and Boelsterli, 1998) and delivered to
more distal sites, i.e., the jejunum and ileum (Boelsterli and
Ramirez-Alcantara, 2011). During this transport, a portion
of the AG is converted to iso-glucuronides by spontaneous
acyl migration of the aglycone along the sugar ring
(Dickinson and King, 2001). Diclofenac AG (but not the iso-
glucuronides) can be cleaved by bacterial -glucuronidase in
the lumen of the small bowel. The released DCF is then taken
up by enterocytes and undergoes enterohepatic circulation,
thus re-exposing the mucosa repeatedly. We hypothesized that
the intraluminal release of the parent drug by bacterial -glu-
curonidase could be a key factor in the initiation of NSAID
enteropathy; hence, highly selective inhibition of bacterial
-glucuronidase would protect against intestinal injury.
Because a normal gut flora is important for maintaining a
normal health status, the targeted inhibition of a bacterial
enzyme without killing the bacteria altogether may prove to
be a promising approach. Recently, a number of selective
bacterial -glucuronidase inhibitors were shown to be highly
efficacious against the enzyme target in aerobic and anaero-
bic bacteria without killing the bacteria or inhibiting the
orthologous mammalian enzyme (Wallace et al., 2010). These
inhibitors afforded protection against the intestinal toxicity
associated with the anticancer drug CPT-11 (irinotecan)
through inhibition of the release of the toxic aglycone in the
gut. Here, we aimed at using one of these bacteria-selective
inhibitors, Inhibitor-1 (Inh-1; Fig. 1A), to evaluate its poten-
tially protective effects against the enteric toxicity induced by
DCF in an established mouse model of NSAID enteropathy.
Materials and Methods
Chemicals. Diclofenac was obtained from Sigma-Aldrich (St.
Louis, MO). Inhibitor-1 [1-((6,8-dimethyl-2-oxo-1,2-dihydroquinolin-
3-yl)methyl)-3-(4-ethoxyphenyl)-1-(2-hydroxyethyl)thiourea], as de-
scribed previously (Wallace et al., 2010), was synthesized in house.
Diclofenac-1--O-acyl glucuronide was obtained from LC Scientific,
Inc. (Concord, Ontario, Canada). All chemicals were of the highest
grade available.
Escherichia coli -Glucuronidase Enzyme Inhibition Stud-
ies with Inh-1. Expression and purification of E. coli -glucuroni-
dase was conducted as described previously (Wallace et al., 2010).
DCF-AG assays were performed at 50 l total volume in 96-well
assay plates (Corning Life Sciences, Lowell, MA). Reactions con-
sisted of the following: 25 l of assay buffer (2% DMSO, 100 mM
NaCl, and 100 mM HEPES, pH 6.8), 15 l of substrate (DCF-AG), 5
l of Inh-1 solution, and 5 l of 5 nM enzyme. Each reaction was
quenched with trichloroacetic acid to a final concentration of 10%
trichloroacetic acid. Samples were centrifuged at 13,000g for 10 min
to pellet the precipitate before sample detection. HPLC-UV detection
of the DCF product was carried out in a similar protocol as reported
previously (Seitz et al., 1998) using a Phenomenex Luna 5 m C18(2)
reverse-phased HPLC column. The AUC for the peak corresponding
to the product DCF was calculated for each inhibitor concentration.
Animals and Treatment. Male C57BL/6J mice were obtained
from The Jackson Laboratory (Bar Harbor, ME). The mice were
acclimatized for 3 weeks before the experiment and were 10 to 12
weeks of age at the start of the experiments. The animals were kept
on a 14/10-h light/dark cycle. They received mouse chow (Teklad
Global Rodent Diet; Harlan Laboratories, Boston, MA) and water ad
libitum. All studies were approved by the Institutional Animal Care
and Use Committee of the University of Connecticut. Diclofenac was
dissolved in 10% (in phosphate-buffered saline) Solutol HS-15 solu-
tion and administered intraperitoneally in a volume of 10 l/g b.wt.
The ulcerogenic dose (60 mg/kg) was chosen based on a previous
dose-response analysis (Ramirez-Alcantara et al., 2009). Also, we
have previously shown in rats that the extent of small intestinal
injury was qualitatively and quantitatively similar for both peroral
or intraperitoneal routes of administration, because the development
of enteropathy critically depends on portal delivery of DCF to the
liver, followed by hepatobiliary export of DCF conjugates (Seitz and
Boelsterli, 1998). All animals were treated at 5 h before the start of
the dark cycle. Inhibitor-1 or vehicle (0.5% methyl cellulose) was
administered by oral gavage b.i.d. (10 g per mouse), starting 1 day
before DCF administration and with the last dose given 1 h before
DCF to minimize drug-drug interactions. This daily dose of Inh-1
was adopted from a previous mouse study where it has proven to be
effective in inhibiting intestinal bacterial -glucuronidase (Wallace
et al., 2010). Control animals received methyl cellulose and/or Solu-
tol HS-15.
Assessment of Intestinal Permeability In Vivo. Intestinal
permeability changes were determined as described previously (Na-
politano et al., 1996), with minor modifications. In brief, mice were
administered FITC-dextran (4 kDa) by oral gavage (400 mg/kg, in
0.5% methyl cellulose) 3 h before blood collection by cardiac punc-
ture. Serum was prepared and stored at 80°C until used. After
dilution of the serum (1:10), fluorescence was recorded in black
96-well plates at   490 nm/530 nm (excitation/emission, respec-
tively). The fluorescence measurements were linear with respect to
the concentration range, and the absolute values were determined
with a standard curve.
Assessment of Small Intestinal Injury. Enteropathy was as-
sessed and graded as described previously (Ramirez-Alcantara et al.,
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2009). In brief, mice were sacrificed by CO2 inhalation at 18 h after
DCF (when the development of mucosal injury was maximal). A
midline incision was made, and blood was obtained via cardiac punc-
ture. Serum was prepared and frozen at 80°C until use for analysis.
The entire small intestine (from the gastroduodenal junction to the
ileocecal junction) was removed and opened longitudinally along the
antimesenteric side. The tissue was rinsed in ice-cold phosphate-
buffered saline and incubated for 15 min in 1 mM nitroblue tetrazo-
lium (NBT) solution containing 16 mM HEPES-NaOH, 125 mM
NaCl buffer, 3.5 mM KCl, and 10 mM glucose. Next, the tissues were
fixed in 10% zinc formalin for 24 h, washed, and transferred to 70%
ethanol. The intestine was metrically divided into four quartiles of
equal length and evaluated at 10 magnification for quantitative
and qualitative analysis of mucosal injury, and the lesions were
assigned to the respective quartiles. The following scoring system
was used: 0, no apparent lesions; 1, small erosions or ulcers (	0.1
mm); 2, medium ulcers (0.1–0.8 mm); 3, large confluent ulcers (0.8
mm). In addition, the total area of the lesions was quantified by
ImageJ software. The formalin-fixed tissue was embedded in paraf-
fin, and 5-m sections were stained with hematoxylin/eosin for his-
topathological evaluation. Serum activity of alkaline phosphatase
was measured with a kinetic colorimetric kit (BioAssay Systems,
Hayward, CA).
Pharmacokinetic Profiling of Diclofenac in Mice. To deter-
mine whether inhibition of bacterial -glucuronidase might alter the
disposition of DCF and its overall systemic exposure, the plasma
concentration versus time curve of DCF alone was compared with
that of combined Inh-1/DCF treatment. Mice were administered
Inhibitor-1 (10 g per mouse, b.i.d., for 2 days; n  9) or vehicle (0.5%
methyl cellulose; n  9), followed by DCF (60 mg/kg i.p.). From each
mouse, maximally three blood samples were serially collected by
retro-orbital puncture, so that for each time point, samples were
collected from three mice. Blood samples (120 l) were obtained at
0.16, 0.5, 1, 2, 4, 8, and 24 h after dose. Immediately after collection,
plasma was prepared and stored below 70°C until analysis. All
samples were processed for analysis by precipitation using acetoni-
trile and analyzed by LC-MS/MS (Sai Advantium Pharma Ltd.,
Pune, India), with a lower limit of quantitation for diclofenac of 5.0
ng/ml. In brief, an ACE 3 C18 column (150  4.6 mm; 3.5 m) was
used; the mobile phase for gradient elution consisted of 5 mM am-
monium formate in water and acetonitrile. Mass spectrometry was
performed with an API 4000 (AB Sciex, Framingham, MA) equipped
with a turbo ion spray source. The Noncompartmental-Analysis
module in WinNonlin (version 5.2; Pharsight, Mountain View, CA)
was used to assess the pharmacokinetic parameters.
Statistical Analysis. All data were expressed as mean 
 S.D. If
there was normal distribution, a standard analysis of variance was
used, followed by Dunnett’s test for multiple comparisons versus the
control group. When normality failed, a Kruskal-Wallis one-way
analysis of variance on ranks was used followed by Dunn’s test for
multiple comparison versus the control group. A P value of 	 0.05
was considered statistically significant.
Results
Inhibitor-1 Is a Potent Inhibitor of E. coli -D-Glucu-
ronidase Diclofenac 1--O-Acyl Glucuronide Cleavage.
To test our hypothesis that Inh-1 would prevent the enzy-
matic hydrolysis of luminal DCF-AG by enteric bacterial
-D-glucuronidase, we first determined whether DCF-AG
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Fig. 1. Diclofenac-1--O-acyl glucuronide as a substrate for E. coli -glucuronidase and inhibition of enzymatic hydrolysis by Inh-1. A, chemical
structure of Inhibitor-1 and conjugation-deconjugation cycling of DCF and its inhibition by Inh-1. UGT2B7, uridine diphosphate glucuronosyl
transferase 2B7; UDPGA, uridine diphosphate glucuronic acid. B, in vitro studies with purified E. coli -glucuronidase and DCF-AG (4 mM) were
performed as described under Materials and Methods. Enzymatic generation of the product, free DCF, was assessed by HPLC analysis. Inhibitor-1
caused a concentration-dependent inhibition of product formation.
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fied E. coli -glucuronidase converted DCF-AG (various con-
centrations) to its aglycone in vitro (Fig. 1B). Next, to assess
the inhibition characteristics of Inh-1, we added increasing
concentrations of the inhibitor to the incubation system con-
taining 4 mM DCF-AG. Inhibitor-1 decreased the release of
free DCF in a concentration-dependent manner, resulting in
90% inhibition at 100 M inhibitor (Fig. 1B). The IC50
value was calculated to be 164 
 11 nM (n  3 independent
experiments). Previous studies had revealed that the inhibi-
tion of bacterial -glucuronidase by Inh-1 exhibits uncom-
petitive characteristics (Wallace et al., 2010). These data
demonstrate 1) that bacterial -D-glucuronidase is involved
in the hydrolytic cleavage of DCF-AG and 2) that Inh-1
inhibits this reaction with a high potency in the low nano-
molar range.
Inhibitor-1 Protects Mice from Diclofenac-Induced
Small Intestinal Ulceration. We hypothesized that if
Inh-1 inhibited bacterial -D-glucuronidase activity in vivo,
then this should lead to less DCF-AG being hydrolyzed in the
small intestine and to smaller amounts of released DCF
interacting with the mucosa. Therefore, to determine the
toxicologic consequences of inhibiting intestinal bacterial
-glucuronidase, we treated mice with a single ulcerogenic
dose of DCF (60 mg/kg, i.p.) with or without pretreatment
with Inh-1 (10 g per mouse, b.i.d, for 2 days) and analyzed
the extent of drug-induced enteropathy. As expected, mice
receiving DCF alone developed typical NBT-positive areas of
ulceration in the jejunum and ileum (Fig. 2A), whereas ve-
hicle controls did not exhibit any apparent pathological le-
sions. In contrast, in mice pretreated with Inh-1, DCF caused
only few isolated and small NBT-positive areas. Histopatho-
logical analysis of these lesions revealed that DCF induced
typical ulcers characterized by loss of villi and an inflamma-
tory response, involving the entire mucosa (Fig. 2B), whereas
pretreatment with Inh-1 largely prevented these changes.
Quantitative analysis revealed that the ulcers, which were
abundant in DCF-alone-treated mice in quartiles 3 and 4,
were greatly reduced both in size and number after cotreat-
ment with Inh-1 (Fig. 3, A and B). Likewise, the DCF-asso-
ciated decrease in serum alkaline phosphatase activity (an
established biomarker of enteropathy) (Ramirez-Alcantara et
al., 2009) was largely prevented by Inh-1 pretreatment (Fig.
3D). Furthermore, the transmucosal permeability of FITC-dex-
tran (a high-molecular-weight, nonmetabolizable branched glucan
labeled with fluorescein, which normally is poorly absorbed into
the systemic circulation) was increased by almost 2-fold after DCF
alone but remained at vehicle control levels after pretreatment
with Inh-1 (Fig. 3C). Together, these data indicate that Inh-1
afforded significant protection from DCF-induced acute small in-
testinal injury in mice.
Effects of Inh-1 on DCF Pharmacokinetics. To assess
whether inhibition of intestinal bacterial hydrolysis of DCF
glucuronides would alter the disposition of DCF, and thus
potentially impair its pharmacologic efficacy at the target
tissues, we conducted a pharmacokinetic study in mice after
a single administration of DCF (60 mg/kg) with and without
pretreatment with Inh-1 (Fig. 4). Analysis of the DCF plasma
level over time curve revealed that there was a typical biex-
ponential decrease in plasma concentration with an apparent
Tmax of 10 min and an apparent Cmax in the high micromolar
range (Table 1). Pretreatment with Inh-1 did not signifi-
cantly change these parameters, and the overall systemic
exposure to DCF (AUC0–24h) was not significantly different
from that in DCF-alone-treated mice (exposure ratio vehicle
group/Inh-1 group was 0.99). These data indicate that the
amount of DCF acyl glucuronide (and possibly other glucuro-
Vehicle control DCF DCF + Inhibitor-1
A
B
Vehicle control                           DCF                  DCF + Inhibitor-1
Vehicle control                           DCF                  DCF + Inhibitor-1
Fig. 2. Macroscopic and histopathologic assessment of mu-
cosal damage in mouse jejunum 18 h after DCF adminis-
tration with and without pretreatment with Inh-1. A, mac-
roscopic view of the luminal side of the jejunum; note the
large ulcers (arrow) in DCF-treated mice and the absence
of any large ulceration in the Inh-1/DCF-cotreated mice.
After Inh-1/DCF cotreatment, erosions or single small ul-
cers were present (white arrow) (NBT staining; 10 mag-
nification). B, representative histopathological sections of
the jejunum; note the ulcer in the DCF-treated mouse
involving the entire mucosa and characterized by an in-
flammatory response (arrow). These lesions are not present
in Inh-1/DCF-cotreated mice (hematoxylin and eosin; 40
magnification).
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nide metabolites) excreted into the bile and reaching the
lower GI is sufficient to trigger mucosal injury to the small
intestine, but not high enough to significantly alter the sys-
temic exposure if its hydrolytic cleavage is prevented by the
bacterial -glucuronidase inhibitor.
Discussion
The purpose of this study was to test the hypothesis that



































Fig. 4. Effect of Inh-1 on the pharmacokinetic profile of DCF. Male
C57BL/6 mice were administered a single dose of DCF (60 mg/kg, i.p.)
with or without pretreatment with Inh-1 (10 g per mouse, b.i.d., for 2
days). Serial blood sampling was performed at the indicated time points.
Diclofenac plasma concentrations were determined by LC-MS/MS as
described under Materials and Methods. Data points are mean 
 S.D.
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Fig. 3. Protection from diclofenac-induced small intestinal ulceration by Inh-1 pretreatment. Male C57BL/6 mice were administered a single
intraperitoneal dose of DCF (60 mg/kg) or vehicle (10% Solutol HS-15) after pretreatment with Inh-1 (10 g per mouse, p.o., b.i.d.) or vehicle (0.5%
methyl cellulose) for two consecutive days. A, the average ulcer area was determined by morphometric analysis of photomicrographs using ImageJ
software. The quartile numbers (Q1–Q4) are assigned to four small intestinal segments of equal length from the gastroduodenal junction to the
ileocecal junction. Data are mean 
 S.D. (n  7 mice per group). , P 	 0.05 versus DCF alone in the respective quartile. B, average large ulcer number
(score 2 or higher). Data are mean 
 S.D. (n  7). , P 	 0.05 versus DCF alone in the respective quartile. C, serum FITC-dextran levels as an
indication of intestinal permeability. FITC-dextran was orally administered (400 mg/kg) 15 h after DCF, and blood was collected 3 h later. Data are
mean 
 S.D. (n  5). , P 	 0.05 versus vehicle control; #, versus DCF alone. D, serum alkaline phosphatase activity 18 h after DCF. Data are mean 

S.D. (n  5). , P 	 0.05 versus vehicle control; #, versus DCF alone.
TABLE 1
Effects of Inh-1 on the pharmacokinetic parameters of diclofenac
Male C57BL/6 mice were pretreated with Inh-1 (10 g p.o., per mouse) or vehicle
(0.5% methyl cellulose) b.i.d. for 2 consecutive days. Diclofenac (60 mg/kg i.p.) was
administered 1 h after the last dose of Inh-1. Blood was drawn after 0.16, 0.5, 1, 2,
4, 8, and 24 h after diclofenac, and plasma drug concentrations were determined by
LC-MS/MS. The data are mean 
 S.D. (n  3 mice for each time point; maximally
three serial sampling times per mouse).
Treatment Tmax Cmax AUC0–24 h T1/2
h ng/ml ng/ml * h h
Diclofenac 0.16 264,868 
 46,216 208,425 2.82
Diclofenac  Inh-1 0.16 240,115 
 18,020 210,014 2.77
T1/2, half-life.
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idase by a bacteria-specific small-molecule inhibitor would
protect the small intestinal mucosa from DCF-induced ulcer-
ation. This concept was based on the hypothesis that inhibi-
tion of the catalytic release of the parent aglycone from the
AG or other glucuronides would greatly reduce the high local
exposure of the mucosa to the aglycone and thus alleviate
toxicity. We found that one of the previously characterized
selective bacterial -D-glucuronidase inhibitors, Inh-1 (Wal-
lace et al., 2010), indeed afforded significant protection
against an ulcerogenic dose of DCF in mice. This conclusion
was based on two major experimental findings. First, puri-
fied E. coli -glucuronidase readily catalyzed the deconjuga-
tion of DCF-AG to DCF in vitro, confirming that DCF-AG is
a substrate for bacterial -glucuronidase. Inhibitor-1 turned
out to be a highly potent inhibitor of this reaction, exhibiting
an IC50 value in the low nanomolar range. With regard to
specificity, previous studies had clearly demonstrated that
Inh-1 did not inhibit the mammalian orthologs of -glucuron-
idase (Wallace et al., 2010), supporting the concept that the
enzyme function in the host enterocytes remained unaffected
and that the bacterial form was the major target. Second,
pretreatment with Inh-1 prevented the DCF-induced in-
creases in intestinal permeability and reduced the mucosal
ulceration to near-vehicle control levels as inferred from mac-
roscopic, histopathologic, and clinical-chemical data analysis.
The importance of luminal bacteria in the development of
NSAID enteropathy has been recognized for a long time;
however, this has been traditionally ascribed to the initiation
of an inflammatory reaction through lipopolysaccharide-me-
diated activation of Toll-like receptor 4 (Scarpignato, 2008;
Watanabe et al., 2008). Although this is important in the
propagation and amplification of the inflammatory response,
we show here that the luminal bacteria play an equally
crucial role in the early pathogenesis of NSAID toxicity by
catalyzing the release of the parent compound from its gluc-
uronide conjugate. The data also provide novel insights into
the previous uncertainties of whether AGs, which are elec-
trophilic species with differential reactivity toward protein
targets, might be directly involved in the toxicity of carbox-
ylic acid-containing drugs (Spahn-Langgut et al., 2007;
Boelsterli and Ramirez-Alcantara, 2011). If DCF-AG were
indeed the toxic species, as opposed to the free parent drug or
certain oxidative metabolites, then coadministration of Inh-1
would increase the degree of enteropathy rather than protect
from it. Thus, the traditional concept stating that NSAID
AGs are critically involved in intestinal toxicity (Seitz and
Boelsterli, 1998) can now be clarified to the following: gluc-
uronide metabolites remain critical, but they may merely be
a transport form delivering the drug from the liver to more
distal sites in the GI tract, i.e., the jejunum and ileum
(Boelsterli and Ramirez-Alcantara, 2011).
This revised concept may also provide a possible explana-
tion why rodents are extremely sensitive to NSAID enterop-
athy, which may be related to the route of NSAID metabolite
excretion. Rodents, especially rats, secrete higher levels of
glucuronides into bile, because of the lower molecular weight
cutoff (300–400 Da) at the canalicular plasma membrane
(Klaassen and Watkins, 1984), and DCF glucuronides are
clearly above this threshold. For example, DCF administra-
tion to gallbladder-cannulated mice revealed that the
amount of biliary DCF-AG was 117-fold higher than that of
the parent DCF and 22-fold higher than that of ring-hydroxy-
lated DCF (Lagas et al., 2010). In contrast, the canalicular
export cutoff in humans is higher (500 Da) (Bailey and
Dickinson, 1996), and a larger portion of glucuronides are
excreted renally rather than via the hepatobiliary route.
Nevertheless, a considerable amount of DCF is excreted via
bile in humans; initial studies had estimated this to be 10 to
20% (Stierlin et al., 1979), but subsequent studies had re-
vealed that approximately 75% of total DCF clearance was in
the form of glucuronides, including AGs of the major oxida-
tive metabolite, 4-hydroxy-DCF (Kumar et al., 2002).
If such a large proportion of an administered dose of DCF
is excreted via the hepatobiliary route [42% of [14C]-DCF
equivalents appeared in bile for 60 min after intravenous
administration of 5 mg/kg in mice (Lagas et al., 2010)], then
the question may arise why inhibition of glucuronide cleav-
age by bacterial -glucuronidase did not have any apparent
effects on the DCF plasma level versus time curve (Fig. 4 and
Table 1). A plausible reason may be that in mice the amount
of DCF-AG in bile was only 4% of the dose; the remaining
conjugated metabolites (30% of the dose) were iso-glucu-
ronides (which are not a substrate for -glucuronidase),
glucuronides of the 4-hydroxy or 5-hydroxy metabolites (La-
gas et al., 2010), or even taurine conjugates (Sarda et al.,
2012). Thus, despite the inhibition of the bacterial enzyme, the
therapeutic efficacy of the NSAID probably remains intact.
Apart from bacterial -glucuronidase, NSAID acyl glucu-
ronides can also be cleaved to their aglycone by other en-
zymes. For example, it has been previously demonstrated in
a guinea pig model that tissue esterases can hydrolyze intra-
venously administered zomepirac acyl glucuronide, because
this reaction was inhibited by the nonspecific esterase inhib-
itor, phenylmethylsulfonyl fluoride (Smith et al., 1990). Co-
treatment with phenylmethylsulfonyl fluoride decreased the
futile cycling of the parent zomepirac and its glucuronide and
increased the plasma clearance of zomepirac. However, these
studies only addressed the role of systemic esterases; in fact,
the experiments were performed in bile duct-ligated animals
to prevent biliary clearance. As to intestinal enzymes, a
study using rat intestinal homogenates and the NSAID difl-
unisal has revealed that esterases are quantitatively less
important than -glucuronidases in cleaving the acyl gluc-
uronide (Dickinson and King, 2001). Because luminal bacte-
rial -glucuronidase interacts with the glucuronides before
the drug is absorbed, and because specific inhibition of bac-
terial -D-glucuronidase by Inh-1 greatly decreased the ex-
tent of enteropathy in this present study, it is reasonable to
conclude that the enteric bacteria play a key role in the local
liberation of the parent NSAID and in the subsequent initi-
ation of enteropathy.
Intestinal epithelial cells also express -glucuronidase ac-
tivity (primarily in the endoplasmic reticulum), but the role
of these host enzymes, as opposed to the bacterial enzyme, in
the cleavage of NSAID glucuronides remains less clear. How-
ever, the findings that human intestinal microsomes (in con-
trast to liver microsomes) did not cleave a number of distinct
glucuronide substrates (Oleson and Court, 2008) supports
the concept that bacteria are more important in the hydro-
lysis of luminal glucuronides. Indeed, Inh-1 is highly specific
for bacterial -glucuronidase and has no apparent inhibitory
effects on the mammalian orthologous enzyme (Wallace et
al., 2010) or on intestinal carboxylesterases (M. Redinbo,
unpublished data).
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In addition to enzymatic cleavage, NSAID glucuronides
can also undergo spontaneous, nonenzymatic hydrolysis to
generate the aglycone. For example, acyl glucuronides, which
are stable at acidic pH (	5), can readily undergo hydrolytic
cleavage at increasing pH (Regan et al., 2010). It is notewor-
thy that the pH in mouse small intestine has been reported to
exhibit little variation along the jejunum and ileum, ranging
between 4.8 (fed state) and 5.0 to 5.2 (fasted state) (McCon-
nell et al., 2008). Thus, the contribution of spontaneous hy-
drolysis in the generation of parent DCF probably plays a
minor role in mice compared with the enzymatic, -glucuron-
idase-catalyzed release of the free drug.
The hepatic metabolism of DCF in mice is complex, and
a recent study has revealed that at least 37 distinct me-
tabolites are generated (Sarda et al., 2012). Among these
are not only acyl (ester) glucuronides but also phenol
(ether) glucuronides, generated from 4-hydroxy and 5-hy-
droxy DCF intermediates. These phenol glucuronides are
distinct from the acyl glucuronide in their chemical stabil-
ity, and they lack the reactivity toward nucleophilic tar-
gets. However, the findings that the ether glucuronides
were excreted primarily in the urine of mice (Sarda et al.,
2012) suggest that these metabolites may play a minor role
in the enteric toxicity of DCF.
With a view to potential clinical applications of this novel
concept, we note the following. First, it has been previously
suggested that therapeutically altering the intestinal micro-
flora, e.g., by administration of poorly absorbable antibiotics,
might provide an enteroprotective therapy against NSAID
toxicity (Scarpignato, 2008). However, this approach could
have serious adverse effects in patients because a normal
commensal microflora is essential. Second, strategies that
have been traditionally used to protect the upper GI from
NSAID ulceration, i.e., coadministration of proton pump in-
hibitors, do not protect the small intestine but rather can
exacerbate NSAID enteropathy, as a result of a shift in the
number of specific types of enteric bacteria (Wallace et al.,
2011). Here, we propose an alternative strategy that includes
the use of a bacteria-specific -glucuronidase inhibitor that
leaves the intestinal microbiome intact (Wallace et al., 2010).
In conclusion, we have demonstrated that pharmacologic
targeting of luminal -D-glucuronidase with a small-molecule
inhibitor of the bacterial enzyme protects the GI against
DCF-induced enteropathy. Because this inhibitor is highly
specific for bacterial -D-glucuronidase and does not affect
mammalian -glucuronidases or kill bacteria or mammalian
cells (Wallace et al., 2010), this approach is novel and could
have potential clinical implications. In view of the increased
life expectancy in developed countries and the associated
shifts in the demographic patterns, there will, undoubtedly,
be an increased future demand for antirheumatic drugs. Fur-
thermore, because of the known risks of the selective COX-2
inhibitors for developing cardiovascular complications, many
health professionals will increasingly prescribe the more tra-
ditional NSAIDs (nonselective COX inhibitors). Therefore,
the development of novel strategies to prevent NSAID-in-
duced enteropathy is both timely and topical. Among these,
an evaluation of Inh-1-type bacterial -glucuronidase inhib-
itors merits further exploration as potentially potent and
safe protective agents against NSAID-induced enteropathy.
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